Blade Therapeutics announced Monday morning that the company and its proposed merger partner, Biotech Acquisition Company, mutually agreed to call things off, effective immediately. This takes place just seven months after Blade, the small San Francisco biotech where ex-Purdue CEO Mark Timney is board chair, announced the reverse merger worth $254.3 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,